Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
Immune cells are significantly involved in DbCM progression, impacting myocardial homeostasis and HF progression. Neprilysin inhibition by Sacubitril/Valsartan improved adverse cardiac remodelling in experimental DbCM through direct regulation of inflammation, highlighting immunomodulation as a novel mechanism underlying established its cardioprotective actions.
Authors
- Mark Ledwidge (ORCID: https://orcid.org/0000-0001-7391-2949)
- Kenneth McDonald (ORCID: https://orcid.org/0000-0001-8011-3301)
- David Grieve (ORCID: https://orcid.org/0000-0002-3655-7754)
- Kevin J. Edgar (ORCID: https://orcid.org/0000-0002-9459-9477)
- Chris Watson (ORCID: https://orcid.org/0000-0001-8749-0732)
- Narainrit Karuna (ORCID: https://orcid.org/0000-0002-4050-7469)
- Lauren Kerrigan (ORCID: https://orcid.org/0000-0001-9185-4666)
Institutions
- Queen's University Belfast (GB)
- Chiang Mai University (TH)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1186/s12933-025-02741-5
- Citations
- 6
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 8.33
Funders
- British Heart Foundation
- Queen's University Belfast